Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
9.45
-0.10 (-1.05%)
Mar 31, 2025, 1:27 PM EDT - Market open
Alvotech Employees
Alvotech had 999 employees as of December 31, 2023. The number of employees increased by 82 or 8.94% compared to the previous year.
Employees
999
Change (1Y)
82
Growth (1Y)
8.94%
Revenue / Employee
$492,470
Profits / Employee
-$232,096
Market Cap
2.85B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 999 | 82 | 8.94% |
| Dec 31, 2022 | 917 | 133 | 16.96% |
| Dec 31, 2021 | 784 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ALVO News
- 2 days ago - This Is a Test From GlobeNewswire - GlobeNewsWire
- 4 days ago - Alvotech (ALVO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer - GlobeNewsWire
- 4 days ago - Alvotech Reports Record Results for 2024 and Provides Business Update - GlobeNewsWire
- 4 days ago - Alvotech Reports Record Results for 2024 and Provides Business Update - GlobeNewsWire
- 5 days ago - UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewsWire
- 5 days ago - UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) - GlobeNewsWire
- 11 days ago - Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production - GlobeNewsWire